Sightful Invest
  • Business
  • Investing
  • Politics
  • Stock
Top Posts
Trump considers tax hike on Americans making $2.5...
GOP senators: Congress should vote on Trump’s potential...
White House highlights over $2B in savings from...
GOP talk on millionaire tax hike ‘makes no...
Trump’s first vice president urges his old boss...
Department of Justice opens criminal investigation into NY...
Trump claims ‘I don’t know her’ and ‘listened...
Rubio just got an additional job in Trump’s...
OpenAI’s Sam Altman thanks Sen John Fetterman for...
Former Supreme Court Justice David Souter dead at...
  • Business
  • Investing
  • Politics
  • Stock

Sightful Invest

Investing

Radiopharm Theranostics CEO Shares Company Milestones as NASDAQ Listing Nears

by admin November 18, 2024
November 18, 2024
Radiopharm Theranostics CEO Shares Company Milestones as NASDAQ Listing Nears

Description

During a fireside chat with analysts from Brookline Capital Markets, Radiopharm Theranostics’ (ASX:RAD) CEO Riccardo Canevari provided clinical and corporate updates highlighting the company’s achievements while waiting for the completion of its listing on the NASDAQ expected at the end of 2024.

Canevari provided some updates about the joint venture with MD Anderson Cancer Center and the progress with the B7-H3 targeting radio-antibody (BetaBart). BetaBart is the first targeted radiopharmaceutical against the 4Ig subtype of B7-H3, the most common subtype expressed in human tumors.

“Management is initially targeting small cell lung cancer but sees additional opportunities in colon, renal, lung, cervical, prostate and glioma cancers,” Canevari said. The joint venture is expecting to undertake its first-in-human Phase 1/2 therapeutic trial by mid-2025.

Canevari also outlined the progress of RAD’s focus programs including RAD101 for imaging brain metastases; RAD204 in NSCLC; RAD301 imaging in pancreatic cancer; and RAD202 in breast/gastric:

  • RAD 101, an F18 radiolabeled Pivalate for brain metastases, received FDA IND approval for a Phase 2b trial aiming to enroll 30 patients, with the first dose expected in Q4 2024 and results anticipated mid-2025.
  • RAD 204, a Lu-177-labeled nanobody targeting PD-L1 in NSCLC, recently dosed its first patient in a Phase 1 dose-escalating trial in Australia.
  • RAD 301, a 68Ga-labeled αvβ6-integrin for imaging Pancreatic Ductal Adenocarcinoma, also recently dosed its first patient in a Phase 1 trial at Montefiore Medical Center, building on positive compassionate use data from 99 patients.
  • RAD 402, targeting advanced prostate cancer with Tb-161, which has shown higher tumor uptake compared to Lu-177.

RAD initiated the process to obtain asecondary listing on the Nasdaq Capital Market in 2023, which the company expects to be completed by the end of 2024.

Highlights of the report

  • Clinical Updates — RAD has advanced several clinical programs which include RAD 101 with the first dose expected in Q4 2024.
  • Collaborations with Leading Industry Players — RAD has increased its ownership in Radiopharm Ventures to 75 percent from 51 percent.
  • NASDAQ Listing Expected YE 2024 — RAD is progressing toward a secondary listing on the NASDAQ Capital Market by the end of 2024.
  • Cash Runway Into June 2026 — In June 2024, RAD announced a capital raise of AU$70 million (USD $47million)

For the full analyst report, click here.

This content is intended only for persons who reside or access the website in jurisdictions with securities and other applicable laws which permit the distribution and consumption of this content and whose local law recognizes the scope and effect of this Disclaimer, its limitation of liability, and the legal effect of its exclusive jurisdiction and governing law provisions [link to Governing Law section of the Disclaimer page].

Any investment information contained on this website, including third party research reports, are provided strictly for informational purposes, are general in nature and not tailored for the specific needs of any person, and are not a solicitation or recommendation to purchase or sell a security or intended to provide investment advice. Readers are cautioned to seek the advice of a registered investment advisor regarding the appropriateness of investing in any securities or investment strategies mentioned on this website.


This post appeared first on investingnews.com

previous post
ISLA-101 Phase 2a/b PROTECT Clinical Trial Progress Update
next post
Fetterman calls out ‘UN’s rank, pervasive antisemitism,’ says he looks forward to confirming Elise Stefanik

You may also like

Beyond Lithium Completes Unit Private Placement for Gross...

January 1, 2025

Chemphys Placement Participation Funds Received

January 28, 2025

UAE Suspends 32 Gold Refineries in Anti-Money Laundering...

August 10, 2024

Chinese Copper Smelters to Trim Output in Response...

July 19, 2024

White Cliff Minerals Limited (ASX: WCN) – Trading...

October 14, 2024

Agreement with Vytas Ltd for High Purity Assay...

November 28, 2024

Unlocking a New High-Grade Antimony-Tungsten Structure Adds Potential...

February 25, 2025

Finlay Minerals Enters into Earn-In Agreements with Freeport...

April 21, 2025

Barrick Employees Detained in Mali as Mining Sector...

November 29, 2024

Copper Price 2024 Year-End Review

December 31, 2024

Recent Posts

  • Trump considers tax hike on Americans making $2.5 million or more per year
  • GOP senators: Congress should vote on Trump’s potential Iran nuclear deal
  • White House highlights over $2B in savings from DEI cuts during Trump administration’s first 100 days
  • GOP talk on millionaire tax hike ‘makes no sense,’ Trump White House alum says
  • Trump’s first vice president urges his old boss against raising taxes on wealthy Americans

    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Categories

    • Business (712)
    • Investing (2,058)
    • Politics (2,553)
    • Stock (4)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: sightfulinvest.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 Sightful Invest. All Rights Reserved.